TABLE 2

Serum samples from control subjectsa

SampleSex/age (yr)bPrimary vaccine seriesaP boostDate (mo/day/yr) of:ACT ELISA (U/ml)cTNA (%)dPT ELISA (U/ml)e
Last vaccinationSerum sample
N030M/175 aP+06/02/1012/22/153.704.1
N032M/165 aP+09/27/1012/22/153.3021.1
N033M/135 aP+07/29/1312/22/154.1037.3
N036F/175 aP+08/04/0912/22/159.006.4
N037F/175 DTP+08/26/1012/22/151.606.0
N038F/205 DTP05/22/9912/22/152.303.0
N039F/165 aP+05/25/1001/07/162.505.1
N040F/255wP+04/19/9407/23/1514.107.1
N041F/245wP+08/20/1307/23/1512.5019.0
N042F/255wP+02/20/0807/23/1558.8, 10.3f05.7
N043F/255wP+01/10/1503/30/158.0075.3
N044F/255wP+04/20/1007/23/157.7023.3
N045F/285wP+04/02/1407/23/159.7020.1
N046F/395wP01/27/8516.907.9
N047F/575wP+01/201202/02/123.0037.0
N048F/265wP+08/20/1301/28/1415.3021.9
N049F/275wP+01/22/1001/29/1510.2059.9
N050F/285wP+02/15/1503/30/1512.80106
N051F/245wP+04/24/1102/26/147.4066.0
N052F/255wP+01/10/1501/29/159.8072.9
N053M/395wP01/27/8512.9011.0
N054M/405wP+07/24/0601/10/1217.603.6
  • a Bolded values are considered positive (see titers below). Data represent the mean of the results from each sample tested in duplicate (ELISA) or triplicate (TNA).

  • b M, male; F, female.

  • c ACT titer mean ± SD, 8.85 ± 4.95 U/ml; normal, ≤18.8 U/ml (2 SD).

  • d Percent toxin neutralization using a 1:50 final serum dilution, as described in Materials and Methods.

  • e PT titer mean ± SD, 28.17 ± 29.4 IU/ml; normal, ≤87.0 IU/ml (2 SD).

  • f Titer obtained using catalytic domain as antigen.